Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | FAAH | O00519 | 5/20 | 0.63 |
| ▸ | CNR1 | P21554 | 1/20 | 0.63 |
| ▸ | CNR2 | P34972 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421569 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL22223951 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL8644265 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL365376 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL22710658 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL20969301 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL9768561 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL8419699 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL18187969 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT | |
| SCHEMBL22443356 | 1.00 | LMNA (0.69) | LMNAFAAHCNR1CNR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12508226-B2 | Lipid composition | FUJIFILM CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| US-12370143-B2 | Compound or salt thereof and lipid particles | FUJIFILM CORPORATION (JP) | 2025-07-29 | — | — | US | disclosed |
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-12285525-B2 | Compound or salt thereof and lipid particles | FUJIFILM CORPORATION (JP) | 2025-04-29 | — | — | US | disclosed |
| CN-119039164-B | Ionizable lipid compounds, lipid nanoparticles comprising same, pharmaceutical compositions, pharmaceutical formulations and uses thereof | 国药中生生物技术研究院有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-119039164-A | Ionizable lipid compounds, lipid nanoparticles comprising same, pharmaceutical compositions, pharmaceutical formulations and uses thereof | 国药中生生物技术研究院有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240315970-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORPORATION (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4286012-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3805198-B1 | COMPOUND, SALT THEREOF AND LIPID PARTICLES | FUJIFILM CORP (JP) | 2023-09-20 | — | — | EP | disclosed |
| WO-2020061367-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2019078653-A2 | MODIFIED CONJUGATED DIENE-BASED POLYMER AND METHOD FOR PREPARING SAME | 주식회사 엘지화학 | 2019-04-25 | — | — | WO | disclosed |
| CN-104684538-A | Cosmetic or dermatological composition for moisturizing the skin | OREAL | 2015-06-03 | — | — | CN | disclosed |
| CN-102821743-B | Vaseline-like composition and cosmetic | THE NISSHIN OILLIO GROUP LTD. (JP) | 2014-10-29 | — | — | CN | disclosed |
| US-20140248317-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | GLYTECH, INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-8741871-B2 | Trehalose compound, method for producing same, and pharmaceutical product containing the compound | GLYTECH, INC. (JP) | 2014-06-03 | — | — | US | disclosed |
| EP-2567963-A1 | Trehalose compound, method for producing same, and pharmaceutical product containing the compound | Otsuka Chemical Co., Ltd. (JP) | 2013-03-13 | — | — | EP | disclosed |
| US-20110218171-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-09-08 | — | — | US | disclosed |
| EP-2351764-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | Otsuka Chemical Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
| CN-102106789-A | Cosmetic composition containing at least two volatile straight-chain alkanes and at least one nonprotein cationic polymer | OREAL | 2011-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324859-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | LNPK, PLTP, PLIN3 | LMNA 1539/4885FAAH 3137/4885CNR1 3620/4885 |
| US-12370143-B2 | Compound or salt thereof and lipid particles | NR1H3, NR1H2, LDLR | LMNA 2518/4885FAAH 1917/4885CNR1 93/4885 |
| US-20110218171-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | TREH, MAN2B1, NFATC1 | LMNA 1927/4885FAAH 3687/4885CNR1 820/4885 |
| US-12285525-B2 | Compound or salt thereof and lipid particles | NR1H3, NR1H2, LDLR | LMNA 2518/4885FAAH 1917/4885CNR1 93/4885 |
| US-20240315970-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | NR1H3, NR1H2, LDLR | LMNA 2518/4885FAAH 1917/4885CNR1 93/4885 |
| US-20140248317-A1 | TREHALOSE COMPOUND, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL PRODUCT CONTAINING THE COMPOUND | TREH, MAN2B1, NFATC1 | LMNA 1927/4885FAAH 3687/4885CNR1 820/4885 |
| US-20260102348-A1 | COMPOUND OR SALT THEREOF AND LIPID PARTICLES | LDLR, NR1H3, NR1H2 | LMNA 1252/4885FAAH 3106/4885CNR1 575/4885 |
| US-12508226-B2 | Lipid composition | APOB, NAF1, SLC27A1 | LMNA 1148/4885FAAH 1313/4885CNR1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.